section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Exercise Extreme Caution in:

Adv. Reactions/Side Effects

CV: hypotension, chest pain, edema

Derm: flushing, rash

F and E: hyperkalemia

GI: diarrhea, dyspepsia

GU: impaired renal function

MS: myalgia

Neuro: dizziness, fatigue, headache

Resp: cough

Misc: ANGIOEDEMA, flu-like symptoms

Interactions

Drug-drug:

Drug-Food:

Availability

(Generic available)

Route/Dosage

Renal Impairment

US Brand Names

Univasc

Action

  • Angiotensin-converting enzyme (ACE) inhibitors block the conversion of angiotensin I to the vasoconstrictor angiotensin II. ACE inhibitors also prevent the degradation of bradykinin and other vasodilatory prostaglandins. ACE inhibitors also plasma renin levels and aldosterone levels. Net result is systemic vasodilation.
Therapeutic effects:
  • Lowering of BP in hypertensive patients.

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: ace inhibitors

Pharmacokinetics

Absorption: 13% bioavailability as moexiprilat following oral administration ( by food).

Distribution: Crosses the placenta.

Protein Binding: Moexipril: 90%; Moexiprilat: 50–70%.

Metabolism/Excretion: Converted by liver and GI mucosa to moexiprilat, the active metabolite; 13% excreted in urine, 53% excreted in feces.

Half-Life: Moexipril: 1 hr; Moexiprilat: 2–9 hr ( in renal impairment).

Time/Action Profile

(antihypertensive effect with chronic dosing)

ROUTEONSETPEAKDURATION
POwithin 1 hr4 wkup to 24 hr



Patient/Family Teaching

Pronunciation

moe-EKS-i-pril